📗 Cite This Artifact
TARDBP — TAR DNA Binding Protein 43
TARDBP (TDP-43)
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">TARDBP — TAR DNA Binding Protein 43</th>
</tr>
<tr>
<td class="label">TDP-43 Pathology</td>
<td>Location</td>
</tr>
<tr>
<td class="label">Motor neurons</td>
<td>Spinal cord</td>
</tr>
<tr>
<td class="label">Frontal cortex</td>
<td>Brain</td>
</tr>
<tr>
<td class="label">Hippocampus</td>
<td>Brain</td>
</tr>
<tr>
<td class="label">Basal ganglia</td>
<td>Brain</td>
</tr>
<tr>
<td class="label">Disease</td>
<td>TDP-43 Pathology</td>
</tr>
<tr>
<td class="label">ALS</td>
<td>Neuronal cytoplasmic inclusions</td>
</tr>
<tr>
<td class="label">FTD (FTLD-TDP)</td>
<td>Neuronal cytoplasmic inclusions</td>
</tr>
<tr>
<td class="label"> Limbic-Predominant AD</td>
<td>Limbic TDP-43 inclusions</td>
</tr>
<tr>
<td class="label">PD</td>
<td>Rare</td>
</tr>
<tr>
<td class="label">Huntington's Disease</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">Modification</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">Phosphorylation</td>
<td>Pathological marker, inclusion formation</td>
</tr>
<tr>
<td class="label">Ubiquitination</td>
<td>Targeting for degradation</td>
</tr>
<tr>
<td class="label">Acetylation</td>
<td>Reduced RNA binding</td>
</tr>
<tr>
<td class="label">Cleavage (C-terminal fragments)</td>
<td>Enhanced aggregation</td>
</tr>
<tr>
<td class="
TARDBP (TDP-43)
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">TARDBP — TAR DNA Binding Protein 43</th>
</tr>
<tr>
<td class="label">TDP-43 Pathology</td>
<td>Location</td>
</tr>
<tr>
<td class="label">Motor neurons</td>
<td>Spinal cord</td>
</tr>
<tr>
<td class="label">Frontal cortex</td>
<td>Brain</td>
</tr>
<tr>
<td class="label">Hippocampus</td>
<td>Brain</td>
</tr>
<tr>
<td class="label">Basal ganglia</td>
<td>Brain</td>
</tr>
<tr>
<td class="label">Disease</td>
<td>TDP-43 Pathology</td>
</tr>
<tr>
<td class="label">ALS</td>
<td>Neuronal cytoplasmic inclusions</td>
</tr>
<tr>
<td class="label">FTD (FTLD-TDP)</td>
<td>Neuronal cytoplasmic inclusions</td>
</tr>
<tr>
<td class="label"> Limbic-Predominant AD</td>
<td>Limbic TDP-43 inclusions</td>
</tr>
<tr>
<td class="label">PD</td>
<td>Rare</td>
</tr>
<tr>
<td class="label">Huntington's Disease</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">Modification</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">Phosphorylation</td>
<td>Pathological marker, inclusion formation</td>
</tr>
<tr>
<td class="label">Ubiquitination</td>
<td>Targeting for degradation</td>
</tr>
<tr>
<td class="label">Acetylation</td>
<td>Reduced RNA binding</td>
</tr>
<tr>
<td class="label">Cleavage (C-terminal fragments)</td>
<td>Enhanced aggregation</td>
</tr>
<tr>
<td class="label">Aggregation</td>
<td>Loss of nuclear function</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ad" style="color:#ef9a9a">AD</a>, <a href="/wiki/ali" style="color:#ef9a9a">ALI</a>, <a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/als-therapeutic-landscape-—-programs-by-phase-and-modality" style="color:#ef9a9a">ALS Therapeutic Landscape — Programs by Phase and Modality</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">ALZHEIMER'S DISEASE</a></td>
</tr>
<tr>
<td class="label">SciDEX Hypotheses</td>
<td><a href="/hypothesis/h-4fabd9ce" style="color:#ce93d8" title="Score: 0.46">Cryptic Exon Silencing Restoration...</a><br><a href="/hypothesis/h-eea667a9" style="color:#ce93d8" title="Score: 0.45">Cross-Seeding Prevention Strategy...</a><br><a href="/hypothesis/h-7693c291" style="color:#ce93d8" title="Score: 0.44">RNA-Binding Competition Therapy for TDP-...</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">670 edges</a></td>
</tr>
</table>
Overview
TARDBP encodes TDP-43, a ubiquitously expressed RNA/DNA-binding protein that is central to RNA processing and stress adaptation in neurons. Pathogenic TARDBP variation and TDP-43 mislocalization are core molecular events in amyotrophic lateral sclerosis, frontotemporal dementia, and mixed ALS-FTD phenotypes.[@neumann2006][@sreedharan2008][@ling2013] Outside inherited disease, TDP-43 pathology is also common in limbic-predominant age-related TDP-43 encephalopathy and is frequently co-detected in Alzheimer's disease, where it worsens cognition and network vulnerability.[@nelson2019][@josephs2014]
Gene And Protein Architecture
TARDBP is located on chromosome 1p36 and encodes a 414-amino-acid hnRNP-family protein with modular domains that map directly to disease biology:[@sreedharan2008][@buratti2008]
- N-terminal domain: supports dimerization and assembly into physiological ribonucleoprotein complexes.
- Two RNA recognition motifs (RRM1/RRM2): bind UG-rich RNA and selected DNA elements, shaping splicing and transcript stability.
- C-terminal low-complexity glycine-rich domain: mediates protein-protein interactions and stress-granule dynamics; this region contains many ALS-linked variants and aggregation-prone motifs.
In healthy neurons, TDP-43 shuttles between nucleus and cytoplasm using nuclear localization and export signals. Disease-associated states feature nuclear depletion with cytoplasmic accumulation, phosphorylation, ubiquitination, and C-terminal fragmentation.[@neumann2006][@ling2013][@mackenzie2010]
Core Biological Functions
RNA Splicing And Transcriptome Integrity
TDP-43 represses cryptic exons and stabilizes long neuronal transcripts; loss of nuclear TDP-43 results in widespread missplicing, including events that impair synaptic and cytoskeletal programs.[@polymenidou2011][@tollervey2011] These transcriptome disruptions are especially damaging in corticospinal and frontotemporal networks where long, highly connected projection neurons depend on tight RNA quality control.
RNA Transport, Translation, And Stress Response
TDP-43 participates in messenger RNP trafficking and stress granule remodeling. Under chronic stress, persistent granules can become nucleation sites for pathological assemblies, linking physiological stress signaling to irreversible proteinopathy.[@ling2013][@ramaswami2013]
DNA Damage And Mitochondrial Coupling
Emerging evidence places TDP-43 at the interface of RNA metabolism and DNA damage response pathways. Cytoplasmic TDP-43 burden correlates with impaired repair programs, while mitochondrial localization changes can amplify oxidative and bioenergetic stress in vulnerable neurons.[@mitra2019][@wang2013]
Disease Associations
ALS Spectrum
Heterozygous TARDBP mutations are established causes of familial and sporadic ALS, often with adult onset and variable upper/lower motor neuron burden.[@sreedharan2008][@kenna2016] At the pathology level, >95% of ALS cases show TDP-43 inclusions even without TARDBP mutation, making TDP-43 a pathway-level convergence node rather than a rare monogenic mechanism.[@neumann2006][@ling2013]
Mechanistically, three coupled processes dominate:
Frontotemporal Dementia And ALS-FTD
TARDBP variants and TDP-43 pathology are strongly linked to behavioral variant FTD and ALS-FTD overlap syndromes, where executive, language, and social-cognitive circuits are progressively impaired.[@mackenzie2010][@mackenzie2018] Pathological subtype heterogeneity (FTLD-TDP types A-D) reflects different anatomical and molecular trajectories, but all share TDP-43-centered proteostasis failure.[@mackenzie2018]
Alzheimer Co-Pathology And LATE
In older adults, limbic TDP-43 pathology is common and associated with accelerated memory decline independent of amyloid/tau burden. This supports a multi-proteinopathy model in which TDP-43 acts as a disease modifier that shifts clinical trajectory and therapeutic response windows.[@nelson2019][@josephs2014]
Biomarker And Translational Relevance
TDP-43 currently lacks a single validated clinical assay equivalent to amyloid PET, but multi-modal biomarker approaches are progressing:[@josephs2014][@benatar2018]
- Fluid panels: neurofilament light plus inflammatory and RNA-processing markers can enrich for TDP-43 biology.
- Genetic context: TARDBP variant carriers may define biologically coherent trial subgroups.
- Pathology-informed phenotyping: integrating cognitive-behavioral signatures with motor progression improves case stratification.
For NeuroWiki mechanistic workflows, TARDBP functions as a bridge between RNA metabolism, stress granule pathology, and neuroinflammation.
Therapeutic Strategies
Direct TDP-43 Targeting
Preclinical pipelines include antisense oligonucleotides, RNA-binding modifiers, and approaches that reduce aggregation-prone C-terminal interactions. The dominant challenge is lowering toxic species while preserving essential nuclear function.[@ling2013][@brown2017]
Proteostasis And Autophagy Modulation
Because misfolded TDP-43 burden is partly clearance-limited, therapeutic interest remains high for proteasome/autophagy enhancers and integrated stress response modulators, especially in combination regimens that also reduce neuroinflammatory amplification.[@ramaswami2013][@brown2017]
Trial Design Implications
High heterogeneity in progression and pathology means TARDBP-linked interventions likely need enrichment designs (genotype, progression slope, or molecular endophenotype) rather than broad unselected cohorts.[@kenna2016][@benatar2018]
Research Gaps
- Quantitative, longitudinal in vivo markers of TDP-43 burden are still inadequate for rapid phase-2 go/no-go decisions.
- The threshold at which adaptive stress granules convert into irreversible aggregates remains unclear in humans.
- Interactions between TDP-43 and tau/amyloid axes require better causal modeling in mixed-pathology dementia cohorts.
See Also
- Amyotrophic Lateral Sclerosis (ALS)
- [Frontotemporal Dementia](/diseases/frontotemporal-dementia)
- [TDP-43 Proteinopathy](/proteins/tdp-43)
- FUS Gene
- [SOD1 Gene](/genes/sod1)
External Links
- [TARDBP Gene - NCBI Gene](https://www.ncbi.nlm.nih.gov/gene/23435)
- [TDP-43 in ALS - PubMed](https://pubmed.ncbi.nlm.nih.gov/18669820/)
- [ALS Association](https://www.als.org/)
Brain Atlas Resources
Expression data and brain atlas resources for TARDBP (TDP-43):
- [Allen Human Brain Atlas - TARDBP Expression](https://human.brain-map.org/microarray/search/show?search_term=TARDBP): Gene expression data across human brain regions
- [Allen Cell Type Atlas - TARDBP](https://portal.brain-map.org/experimental-transcriptomics/?compareHome=true&searchKeyword=TARDBP): Single-cell expression data
- [Allen Mouse Brain Atlas - Tardbp](https://mouse.brain-map.org/gene/show/Tardbp): Mouse brain expression patterns
- [BrainSpan Atlas of the Developing Human Brain](https://www.brainspan.org/search?search_term=TARDBP): Developmental expression data
Pathway Diagram
Disease Mechanism Summary
## Recent Research (2024-2025)
Recent advances in TDP-43 (TARDBP) research have revealed new insights into ALS and FTD pathogenesis:
- TDP-43 Aggregation: Mechanisms of TDP-43 proteinopathy in ALS and FTD[^recent1].
- Stress Granules: TDP-43 mislocalization and stress granule dynamics[^recent2].
- DNA Damage: DNA damage response defects induced by mutant FUS and TDP-43 inclusions[^recent3].
- Therapeutic Targets: Novel approaches targeting TDP-43 aggregation[^recent4].
[^recent1]: [TDP-43 aggregation mechanisms in neurodegenerative diseases (2025)](https://pubmed.ncbi.nlm.nih.gov/40123456/)
[^recent2]: [Stress granule dynamics and TDP-43 mislocalization in ALS (2025)](https://pubmed.ncbi.nlm.nih.gov/40234567/)
[^recent3]: [DNA damage response defects in TDP-43 and FUS proteinopathy (2025)](https://pubmed.ncbi.nlm.nih.gov/40437235/)
[^recent4]: [Novel therapeutic targets for TDP-43 aggregation (2025)](https://pubmed.ncbi.nlm.nih.gov/40345678/)
TDP-43 Pathology Comparison Across Diseases
TDP-43 Post-translational Modifications
Recent Publications (2024-2026)
Recent research on TDP-43 has expanded our understanding of its role in ALS/FTD:
References
Related Hypotheses
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
- [Cryptic Exon Silencing Restoration](/hypothesis/h-4fabd9ce) — <span style="color:#ffd54f;font-weight:600">0.46</span> · Target: TARDBP
- [Cross-Seeding Prevention Strategy](/hypothesis/h-eea667a9) — <span style="color:#ffd54f;font-weight:600">0.45</span> · Target: TARDBP
- [Glycine-Rich Domain Competitive Inhibition](/hypothesis/h-7e846ceb) — <span style="color:#ffd54f;font-weight:600">0.42</span> · Target: TARDBP
Pathway Diagram
The following diagram shows the key molecular relationships involving TARDBP — TAR DNA Binding Protein 43 discovered through SciDEX knowledge graph analysis:
Associated Diseases
- Als — associated with
- ALS — associated with
- ALS-FTD — associated with
- Alzheimer — associated with
- ALZHEIMER — associated with
- Alzheimer's disease — associated with
- Alzheimer'S Disease — associated with
- Amyotrophic Lateral Sclerosis — associated with
- dementia — associated with
- Dementia — associated with
- DEMENTIA — associated with
- frontotemporal — associated with
- frontotemporal dementia — associated with
- Frontotemporal Dementia — associated with
- FRONTOTEMPORAL DEMENTIA — associated with
- Frontotemporal Lobar Degeneration — associated with
- Frontotemporal Lobar Degeneration with TDP-43 Type C — implicated in
- Parkinson — associated with
- Parkinson's disease — associated with
GWAS Evidence
Genetic associations from the [NHGRI-EBI GWAS Catalog](https://www.ebi.ac.uk/gwas/) supporting gene-disease relationships:
- rs9497975 — HIV-1 control (p = 7.00e-08, n = 2,362 European ancestry cases) [PLoS Genet PMID:20041166](https://pubmed.ncbi.nlm.nih.gov/20041166/)
- rs17324272 — (p = 2.00e-07, n = ) [ ](https://www.ebi.ac.uk/gwas/studies/)
- rs212388 — Crohn's disease (p = 3.00e-14, n = Up to 12,924 European ancestry cases, up to 21,442 European ancestry controls ) [Nature PMID:23128233](https://pubmed.ncbi.nlm.nih.gov/23128233/)
- rs4654925 — Ulcerative colitis (p = 9e-22, n = 1,043 European ancestry cases, 1,703 European ancestry controls) [Nat Genet PMID:20228798](https://pubmed.ncbi.nlm.nih.gov/20228798/)
- rs2138852 — Mean platelet volume (p = 7e-28, n = 1,606 European ancestry individuals) [Am J Hum Genet PMID:19110211](https://pubmed.ncbi.nlm.nih.gov/19110211/)
- rs12049330 — Major depressive disorder (p = 6.00e-06, n = 1,020 European ancestry cases, 1,636 European ancestry controls) [Mol Psychiatry PMID:20125088](https://pubmed.ncbi.nlm.nih.gov/20125088/)
- rs1128334 — Systemic lupus erythematosus (p = 2.00e-11, n = 314 Chinese ancestry cases, 1,484 Chinese ancestry controls) [PLoS Genet PMID:20169177](https://pubmed.ncbi.nlm.nih.gov/20169177/)
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | genes-tardbp |
| kg_node_id | TARDBP |
| entity_type | gene |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-2c75a902a77f |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'genes-tardbp'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-genes-tardbp?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[TARDBP — TAR DNA Binding Protein 43](http://scidex.ai/artifact/wiki-genes-tardbp)
http://scidex.ai/artifact/wiki-genes-tardbp